Apimeds Pharmaceuticals US (APUS) Accumulated Expenses (2023 - 2025)

Apimeds Pharmaceuticals US's Accumulated Expenses history runs 3 years deep, the most recent figure standing at $918649.0 for Q4 2025.

• Quarterly Accumulated Expenses rose 55.39% year-over-year to $918649.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $918649.0 (up 55.39% YoY) and the FY2025 annual result came in at $918649.0, up 55.39% from the prior year.
• Accumulated Expenses was $918649.0 for Q4 2025 at Apimeds Pharmaceuticals US, up from $117899.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $918649.0 in Q4 2025 and bottomed at $68878.0 in Q4 2023.
• A 3-year average of $424154.2 and a median of $354545.0 in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 758.32% — and 2025, when it surged 55.39%.
• Apimeds Pharmaceuticals US's Accumulated Expenses stood at $68878.0 in 2023, then surged by 758.32% to $591191.0 in 2024, then jumped by 55.39% to $918649.0 in 2025.
• Business Quant data shows APUS's Accumulated Expenses at $918649.0 in Q4 2025, $117899.0 in Q1 2025, and $591191.0 in Q4 2024.